

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SEGAL ROBERT-MD</u> (Last) (First) (Middle) <u>350 MAIN STREET SUITE 307</u> (Street) <u>DOYLESTOWN PA 18901</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/12/2004</u>	3. Issuer Name and Ticker or Trading Symbol <u>DISCOVERY LABORATORIES INC /DE/ [DSCO]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP-Clinical Research, CMO</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>3,325</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Incentive Stock Option (Right to Buy)</u>	<u>11/05/2002</u>	<u>11/05/2012</u>	<u>Common Stock</u>	<u>20,000</u>	<u>1.89</u>	<u>D</u>
<u>Incentive Stock Option (Right to Buy)</u>	<u>09/21/2001</u>	<u>09/21/2011</u>	<u>Common Stock</u>	<u>55,000</u>	<u>2.1</u>	<u>D</u>
<u>Incentive Stock Option (Right to Buy)</u>	<u>(1)</u>	<u>12/13/2012</u>	<u>Common Stock</u>	<u>80,000</u>	<u>2.75</u>	<u>D</u>
<u>Incentive Stock Option (Right to Buy)</u>	<u>05/10/2001</u>	<u>05/10/2011</u>	<u>Common Stock</u>	<u>15,000</u>	<u>4.09</u>	<u>D</u>
<u>Incentive Stock Option (Right to Buy)</u>	<u>08/01/2000</u>	<u>08/01/2010</u>	<u>Common Stock</u>	<u>75,000</u>	<u>4.344</u>	<u>D</u>
<u>Incentive Stock Option (Right to Buy)</u>	<u>09/15/2000</u>	<u>09/15/2010</u>	<u>Common Stock</u>	<u>16,000</u>	<u>5.063</u>	<u>D</u>
<u>Incentive Stock Option (Right to Buy)</u>	<u>09/12/2003</u>	<u>09/12/2013</u>	<u>Common Stock</u>	<u>35,000</u>	<u>8.079</u>	<u>D</u>

Explanation of Responses:

1. All such options shall vest in their entirety upon the fourth anniversary of the date of the grant or at such earlier time, if ever, upon the receipt by the Company of a New Drug Application (NDA) approval by the United States Food and Drug Administration for Surfaxin for either Respiratory Distress Syndrome in premature infants, Meconium Aspiration Syndrome in full-term infants or Acute Respiratory Distress Syndrome in adults.

/s/ Robert Segal
03/16/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.